Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202694 | 0.98 | MEN1 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL5542597 | 0.94 | MEN1 (0.59) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL6199902 | 0.92 | KMT2A (0.82) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL7393652 | 0.88 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL379160 | 0.88 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL4814264 | 0.88 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL3970912 | 0.88 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| Bicarbonate SCHEMBL4357688 | 0.86 | MEN1 (0.73) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL15011579 | 0.86 | MEN1 (0.73) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1000788 | 0.85 | MEN1 (0.71) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002312-A1 | TETRA- AND PENTASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-04 | — | — | US | claimed |
| US-8288531-B2 | Preparation process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | claimed |
| US-8119797-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-21 | — | — | US | claimed |
| US-20110295000-A1 | PRODUCTION METHOD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | claimed |
| US-20110087021-A1 | NOVEL PREPARATION PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | claimed |
| US-20100152439-A1 | PRODUCTION METHOD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-17 | — | — | US | claimed |
| EP-2188275-A2 | NOVEL PREPARATION PROCESS | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | claimed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | claimed |
| US-7696346-B2 | 2-oxoethyl(1R)-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-[[3,5-dimethyl-4-(phenylmethoxy)phenyl]methyl]-2-[4-(4-morpholinyl)-1-piperidinyl]-1-piperidinecarboxylate; coupling alpha -hydroxy-3,5-dimethyl-4-(phenylmethoxy)-phenylpropionic acid-monosodium salt with 1,3-benzodiazepin compound | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | claimed |
| US-7576101-B2 | Using sulfonamides such as N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-O-[1-methylpiperazin-4-ylcarbonyl]-L-tyrosine isopropyl ester optionally with immunoglobulins, steroids, antiinflammatory agents | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-20030017993-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH | 2003-01-23 | — | — | US | claimed |
| US-20020193312-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-19 | — | — | US | claimed |
| US-6489300-B1 | INHIBITORS OF ADHESION IN THE TREATMENT OF INFLAMMATORY BRAIN DISEASES AND OTHER INFLAMMATORY CONDITIONS | ELAN PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | claimed |
| US-6194448-B1 | ANTIINFLAMMATORY AGENTS; ASTHMA; RHEUMATIC DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION | 2001-02-27 | — | — | US | claimed |
| EP-1071680-A1 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-01-31 | — | — | EP | claimed |
| CN-1265657-A | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | claimed |
| EP-1000051-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999052898-A1 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-21 | — | — | WO | claimed |
| WO-1999006390-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| US-5591737-A | ELASTASE INHIBITORS | MERCK & CO., INC. (US) | 1997-01-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030017993-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | MEN1 1753/4885KMT2A 760/4885NPSR1 1843/4885 |
| US-20110087021-A1 | NOVEL PREPARATION PROCESS | CYP2F1, CYP11B2, CYP11B1 | MEN1 270/4885KMT2A 4366/4885NPSR1 315/4885 |
| US-20020193312-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | MEN1 1753/4885KMT2A 760/4885NPSR1 1843/4885 |
| US-20180002312-A1 | TETRA- AND PENTASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12, HRH4 | MEN1 706/4885KMT2A 3093/4885NPSR1 1953/4885 |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | MEN1 883/4885KMT2A 4776/4885NPSR1 64/4885 |
| US-20110295000-A1 | PRODUCTION METHOD | CYP2F1, CYP7A1, CYP1A1 | MEN1 307/4885KMT2A 4536/4885NPSR1 320/4885 |
| US-20100152439-A1 | PRODUCTION METHOD | CYP2F1, CYP7A1, CYP1A1 | MEN1 307/4885KMT2A 4536/4885NPSR1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.